Drug intelligence / Profile preview

JNJ-86974680 + cetrelimab

Development stage: Unknown
Lead developer: Johnson & Johnson
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

This combination involves JNJ-86974680, a small molecule A2a receptor antagonist developed by Johnson & Johnson, and cetrelimab, an anti-PD-1 monoclonal antibody. JNJ-86974680 is designed to block adenosine-mediated immunosuppression by inhibiting A2a receptors on immune cells, potentially restoring T-cell activity against tumors. Cetrelimab blocks the PD-1 protein, enhancing the immune response against cancer cells. The combination is being studied for its potential in treating advanced non-small cell lung cancer (NSCLC), particularly in enhancing the effectiveness of immunotherapy when combined with radiotherapy.

Targets

ADORA2A (Adenosine A₂A Receptor)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on JNJ-86974680 + cetrelimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-86974680 + cetrelimab.

Explore the full profile